Niemann-pick type C: A potentially treatable disorder?

Practical Neurology

Volumn 13, Issue 6, 2013, Pages 382-385

  Kheder, Ammar ^a   Scott, Camilla ^b   Olpin, Simon ^b   Hadjivassiliou, Marios ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYNOJIRIMYCIN; DRUG DERIVATIVE; ENZYME INHIBITOR; MIGLUSTAT;

ADULT; ARTICLE; BEHAVIOURAL DISORDER; CASE REPORT; CEREBELLAR ATAXIA; COGNITION; DEMENTIA; DYSTONIA; HUMAN; MALE; NIEMANN PICK DISEASE; PATHOPHYSIOLOGY;

BEHAVIOURAL DISORDER; CEREBELLAR ATAXIA; COGNITION; DEMENTIA; DYSTONIA;

1-DEOXYNOJIRIMYCIN; ADULT; ENZYME INHIBITORS; HUMANS; MALE; NIEMANN-PICK DISEASE, TYPE C;

EID: 84887518577     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/practneurol-2013-000525     Document Type: Article

References (14)

1. Niemann A. Ein unbekanntes Krankheitsbild. Jahrbuch fur Kinderheilkunde. Neue Folge 1914;79:1-10.
2. Pick L. Der Morbus Gaucher und die ihm ahnlichen krankheiten. Ergeb Inn Med Kinderheilkd 1926;29:519-627.
3. Crocker AC. The cerebral defect in Tay-Sachs disease and Niemann-Pick disease. J Neurochem 1961;7:69-80.
4. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999;281:249.
5. Brady RO, Filling-Katz MR, Barton NW, et al. Niemann-Pick disease types C and D. Neurol Clin 1989;7:75.
6. Patterson MC, Vanier MT, Suzuki K, et al. Niemann-Pick disease type C; a lipid trafficking disorder. In: Scriver CR, Beaudet AL, Sly WS, et al. eds. The metabolic and molecular bases of inherited disease. 8th edn. New York: Mc Graw Hill, 2001:3611-34.
7. Wraith JE, Baumgartner MR, Bembi B, et al. Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab 2009;98:152-65.
8. Fink JK, Filling-Katz MR, Sokol J, et al. Clinical spectrum of Niemann-Pick disease type C. Neurology 1989;39:1040.
9. Spiegel R, Raas-Rothschild A, Reish O, et al. The clinical spectrum of fetal Niemann-Pick type C. Am J Med Genet A 2009;149A:446-50.
10. Storch J, Xu Z. Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking. Biochim Biophys Acta 2009;1791:671-8.
11. Lachmann RH, Te Vruchte D, Lloyd-Evans E, et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C. Neurobiol Dis 2004;16:654.
12. Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007;6:765.
13. Wraith JE, Pineda M, Sedel F, et al. Miglustat in patients with Niemann-Pick Type C disease (NP-C): a multicentre retrospective survey. In: 58th Annual Meeting of the American Society of Human Genetics; 2008, Philadelphia, USA
14. Wyatt K, Henley W, Anderson L, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 2012;39:265-80.